Ocumension Therapeutics (FRA:5DG)

Germany · Delayed Price · Currency is EUR

0.4920

0.00 (0.00%)

Last updated: Oct 23, 2026, 8:10 AM CEST

Market Cap	422.46M -38.2%
Revenue (ttm)	120.36M +71.8%
Net Income	-16.17M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	24.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42
Open	0.4920
Previous Close	0.4920
Day's Range	0.4920 - 0.4920
52-Week Range	0.4300 - 0.9700
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation,... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 608

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 5DG

Financial Performance

In 2025, Ocumension Therapeutics's revenue was 804.35 million, an increase of 92.75% compared to the previous year's 417.31 million. Losses were -158.82 million, -40.80% less than in 2024.

Financial numbers in CNY Financial Statements